Press "Enter" to skip to content

Patent delisted for Boehringer Ingelheim drug TRADJENTA

0
Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug TRADJENTA

Annual Drug Patent Expirations for TRADJENTA
Tradjenta is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from three suppliers. There are nine patents protecting this drug and one Paragraph IV challenge.

TRADJENTA drug price trends.

Drug patent litigation for TRADJENTA.

This drug has two hundred and ninety-seven patent family members in forty-five countries.

The generic ingredient in TRADJENTA is linagliptin. Three suppliers are listed for this compound. Additional details are available on the linagliptin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Boehringer Ingelheim drug TRADJENTA
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions